Q -TIB Oral tablet Tanzania - English - Tanzania Medicinces & Medical Devices Authority

q -tib oral tablet

cipla limited, india - isoniazid ph.eur /pyridoxine hcl ph.eur/sulfamethoxazole ph.eur/trimethoprim ph.eur - oral tablet - 800/160/300

Isoniazid/Pyridoxine Hydrochloride/ Sulfamethoxazole/Trimethoprim tablets 300 mg/25 mg/800 mg/160 mg Film Coated Tablet 300 MG / 25 MG / 800 MG / 160 MG Tanzania - English - Tanzania Medicinces & Medical Devices Authority

isoniazid/pyridoxine hydrochloride/ sulfamethoxazole/trimethoprim tablets 300 mg/25 mg/800 mg/160 mg film coated tablet 300 mg / 25 mg / 800 mg / 160 mg

mylan laboratories limited, india - isoniazid ph.eur /pyridoxine hcl ph.eur/sulfamethoxazole ph.eur/trimethoprim ph.eur - film coated tablet - 300 mg / 25 mg / 800 mg / 160 mg

Q-TIB Tablets 800mg/300mg/160mg/25mg Tanzania - English - Tanzania Medicinces & Medical Devices Authority

q-tib tablets 800mg/300mg/160mg/25mg

cipla quality chemical industries limited, uganda - isoniazid ph.eur /pyridoxine hcl ph.eur/sulfamethoxazole ph.eur/trimethoprim ph.eur - tablets - 800mg/300mg/160mg/25mg

PLASMA-LYTE 148 (approx. pH 7.4) 1000mL injection bag AHB2544 Australia - English - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 1000ml injection bag ahb2544

baxter healthcare pty ltd - sodium acetate, quantity: 3.68 g/l; potassium chloride, quantity: 370 mg/l; magnesium chloride hexahydrate, quantity: 300 mg/l; sodium gluconate, quantity: 5.02 g/l; sodium chloride, quantity: 5.26 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

PLASMA-LYTE 148 (approx. pH 7.4) 500mL injection bag AHB2543 Australia - English - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 500ml injection bag ahb2543

baxter healthcare pty ltd - sodium gluconate, quantity: 5.02 g/l; sodium acetate, quantity: 3.68 g/l; sodium chloride, quantity: 5.26 g/l; magnesium chloride hexahydrate, quantity: 300 mg/l; potassium chloride, quantity: 370 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

Plasma-Lyte® 148 (pH 7.4) solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

plasma-lyte® 148 (ph 7.4) solution for infusion

baxter holding b.v. - sodium chloride; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate ; sodium gluconate - solution for infusion - 148 (ph 7.4) - solutions affecting the electrolyte balance; electrolytes

FARMALINX LAUNCHER PH INDICATOR AND BUFFERING ADJUVANT Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

farmalinx launcher ph indicator and buffering adjuvant

farmalinx pty ltd - nonyl phenol ethoxylate; phosphoric acid derivatives - soluble concentrate - nonyl phenol ethoxylate emulsifiers & surfactants-noni active 266.2 g/l; phosphoric acid derivatives mineral-phophorus-acid active 375.1 g/l - adjuvant - wetting agent | spreader | surfactant - spreader spray (refer to directions)

CREON 10,000 pancreatic extract 150 mg  capsules bottle Australia - English - Department of Health (Therapeutic Goods Administration)

creon 10,000 pancreatic extract 150 mg capsules bottle

viatris pty ltd - pancreatic extract, quantity: 150 mg (equivalent: amylase, qty 8000 ph eur unit; equivalent: lipase, qty 10000 ph eur unit; equivalent: protease, qty 600 ph eur unit) - capsule, enteric - excipient ingredients: iron oxide yellow; sodium lauryl sulfate; macrogol 4000; iron oxide black; triethyl citrate; titanium dioxide; cetyl alcohol; dimeticone 1000; gelatin; iron oxide red; hypromellose phthalate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

CREON 40,000 pancreatic extract 400 mg capsules bottle Australia - English - Department of Health (Therapeutic Goods Administration)

creon 40,000 pancreatic extract 400 mg capsules bottle

viatris pty ltd - pancreatic extract, quantity: 400 mg (equivalent: protease, qty 1600 ph eur unit; equivalent: lipase, qty 40000 ph eur unit; equivalent: amylase, qty 25000 ph eur unit) - capsule, enteric - excipient ingredients: hypromellose phthalate; iron oxide red; titanium dioxide; sodium lauryl sulfate; macrogol 4000; triethyl citrate; iron oxide black; iron oxide yellow; dimeticone 1000; gelatin; cetyl alcohol - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Prismasol 2 mmoll Potassium Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

prismasol 2 mmoll potassium

baxter healthcare (malaysia) sdn. bhd. - potassium chloride; sodium chloride ph eur; glucose monohydrate, ph eur; magnesium chloride.6h2o ph. eur.; calcium chloride 2h2o; lactic acid.; sodium hydrogen carbonate ph. eur. -